The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety…
Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI PlatformBOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Quris-AI…
Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after…
Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers…
Investments will support new product offerings, US expansion, and development of pathology foundation models. BERLIN and NEW YORK, Oct. 29,…
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release…
VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased…
LUND, SE / ACCESSWIRE / October 28, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed PatentsSecures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior…